Early prediction of mortality risk among severe COVID-19 patients using machine learning
暂无分享,去创建一个
[1] A. Wilder-Smith,et al. Can we contain the COVID-19 outbreak with the same measures as for SARS? , 2020, The Lancet Infectious Diseases.
[2] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[3] D. Lillicrap. Disseminated intravascular coagulation in patients with 2019‐nCoV pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[4] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[5] Ke Ma,et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.
[6] Steve Webb,et al. COVID-19: a novel coronavirus and a novel challenge for critical care , 2020, Intensive Care Medicine.
[7] D. Rajgor,et al. The many estimates of the COVID-19 case fatality rate , 2020, The Lancet Infectious Diseases.
[8] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[9] Max Kuhn,et al. Applied Predictive Modeling , 2013 .
[10] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.
[11] P. Adab,et al. Covid-19: risk factors for severe disease and death , 2020, BMJ.
[12] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[13] D. Heymann,et al. COVID-19: what is next for public health? , 2020, The Lancet.
[14] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[15] G. Onder,et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.
[16] C. Eastin,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.
[17] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[18] C. Weyand,et al. Understanding immunosenescence to improve responses to vaccines , 2013, Nature Immunology.
[19] Kiran Shekar,et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases , 2020, The Lancet Respiratory Medicine.
[20] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[21] Centers for Disease Control and Prevention CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[22] B. Cowling,et al. Rational use of face masks in the COVID-19 pandemic , 2020, The Lancet Respiratory Medicine.
[23] Robert C. Holte,et al. Cost curves: An improved method for visualizing classifier performance , 2006, Machine Learning.
[24] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019 , 2020, medRxiv.
[25] E. Ely,et al. The immunopathogenesis of sepsis in elderly patients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.